Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enbrel, Remicade Anti-TNF Class Labeling Debated By FDA Advisory Cmte.

Executive Summary

Anti-TNF rheumatoid arthritis drug class labeling for tuberculosis risk was discussed by FDA's Arthritis Advisory Committee during an Aug. 17 safety update on Immunex' Enbrel (etanercept) and Centocor's Remicade (infliximab).
Advertisement

Related Content

TNF Inhibitors Should Carry Class Warnings For Lymphoma, CHF – FDA Cmte.
TNF Inhibitors Should Carry Class Warnings For Lymphoma, CHF – FDA Cmte.
TNF inhibitor safety review
TNF inhibitor safety review
Centocor Remicade "Dear Doctor" Letter Warns Against Use In CHF
Centocor Remicade "Dear Doctor" Letter Warns Against Use In CHF
TB Data Collection Should Include Concomitant Medications, Centocor Says
Centocor Remicade Black Box MD Visits Will Be 85% Complete By Aug. 31
Centocor Remicade Black Box MD Visits Will Be 85% Complete By Aug. 31
Amgen Kineret Needs Enbrel Combo Study And Combo Use Warning - Cmte
Advertisement
UsernamePublicRestriction

Register

PS038365

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel